Le Lézard
Classified in: Health
Subjects: PDT, FDA

FDA Clears Next-Generation Wesper Lab For Ongoing Sleep Care


NEW YORK, March 22, 2023 /PRNewswire/ -- Wesper, a leading sleep testing and management service provider, announced today that it received a third clearance from the U.S. Food and Drug Administration (FDA) for its next-generation device. The new device positions Wesper as the first and only platform that allows for important clinical-grade longitudinal data collection over multiple nights to diagnose, titrate, and monitor treatment efficacy over time. The new device comes at an affordable cost and dramatically reduces the operational burden for professionals who need to screen, diagnose, or manage treatment.

Wesper, a leading sleep management provider, announced today it received a third clearance from the FDA.

Sleep testing is a critical component in the diagnosis and treatment of sleep disorders such as sleep apnea, as well as reducing the risk of comorbid conditions such as heart disease or dementia. Traditionally, each patient must undergo a sleep test, which can be time-consuming, expensive, and wasteful. Wesper's new approach eliminates these issues by enabling the reuse of a single sleep test for multiple patients.

"Our commitment to innovation and quality is paving the way for sleep clinics to provide a better experience to their patients with high-fidelity data and insights," said Wesper's CEO, Amir Reuveny. "Our technology revolutionizes sleep care by making sleep management more accessible and affordable for patients while also reducing waste and lowering costs for healthcare providers."

The FDA clearance is a significant milestone for Wesper, which has been developing and refining its technology for several years. The company's approach has been rigorously tested and validated through clinical trials, demonstrating quality data over traditional sleep testing methods.

"Historically, an obstacle for sleep healthcare has been the ability to generate clinically reliable measures of sleep physiology in a patient's home while managing one or more therapies. With this most recent FDA clearance, Wesper can now provide clinical data on a patient's real-time sleep physiology in response to treatment, their adherence to therapy, or the need for additional or combination therapies to resolve sleep issues over time," said Chief Medical Officer Dr. Jeffrey Durmer.

Book a demo to see if Wesper's new clearance can help your clinic become more operationally efficient while saving money and delivering better care.

About Wesper
Wesper is a leading sleep testing and therapy service provider, offering innovative solutions for patients and healthcare providers. With a commitment to excellence in patient care and a focus on cutting-edge technology, Wesper is dedicated to improving the lives of those with sleep disorders.

SOURCE Wesper


These press releases may also interest you

at 17:21
Community Healthcare Trust Incorporated (the "Company") today announced the release of its inaugural Corporate Sustainability Report for the year 2023. This comprehensive report highlights the Company's commitment to environmental stewardship,...

at 17:14
BJC HealthCare, one of the largest nonprofit health care organizations in the United States, and Encompass Health , the nation's largest owner and operator of inpatient rehabilitation hospitals, announce the opening of The Rehabilitation Institute of...

at 17:04
Cano Health, Inc. ("Cano Health" or the "Company"), a leading value-based primary care provider and population health company, today announced a global agreement with the Unsecured Creditors Committee representing the interests of the Company's...

at 17:00
Eupraxia Pharmaceuticals...

at 16:47
Nystrom & Associates, a leading provider of behavioral health care services, today celebrated the expansion of its Hugo, Minn. clinic. The expansion will almost double the clinic's size and will enable more providers to meet the community's mental...

at 16:35
Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:  Today, the FDA announced that registration is open for the two-day virtual public meeting, "FDA's Fifth Online Controlled Substances...



News published on and distributed by: